6125-57-1

Usage

Uses

Used in Chemical Synthesis:
Trans-Methyl4-hydroxycyclohexanecarboxylate is used as a chemical intermediate for the synthesis of various organic compounds. Its unique structure allows it to be a valuable building block in the creation of complex molecules.
Used in Pharmaceutical Industry:
Trans-Methyl4-hydroxycyclohexanecarboxylate is used as a potential pharmaceutical candidate for the development of new drugs. Its carboxylic acid group and cyclohexane ring provide a versatile scaffold for the attachment of functional groups, which can be tailored to target specific biological receptors or enzymes.
Used in Material Science:
Trans-Methyl4-hydroxycyclohexanecarboxylate is used as a component in the development of new materials with unique properties. Its ability to form stable structures with other molecules makes it a promising candidate for use in the creation of advanced materials with applications in various industries.
Used in Research and Development:
Trans-Methyl4-hydroxycyclohexanecarboxylate is used as a research compound for studying its properties and potential applications. Scientists and researchers are interested in understanding its reactivity, stability, and interactions with other molecules, which can provide insights into its potential uses in various fields.

Upstream product

• 186581-53-3 diazomethane 
• 3685-26-5 trans-4-hydroxycyclohexanecarboxylic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 74-88-4 methyl iodide 
• 99-96-7 4-hydroxy-benzoic acid 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 874-61-3 4-oxocyclohexanecarboxylic acid 

Downstream Products

• 1239311-08-0 methyl cis-4-[4-(5-cyclopentyloxymethyl[1.3.4]thiadiazol-2-ylcarbamoyl)phenoxy]cyclohexanecarboxylate 
• 1239311-06-8 cis-4-[4-(5-cyclopentyloxymethyl[1,3,4]thiadiazol-2-ylcarbamoyl)phenoxy]cyclohexanecarboxylic acid 
• 1239310-91-8 cis-4-(4-methoxycarbonylcyclohexyloxy)benzoic acid 
• 1239311-09-1 methyl cis-4-(4-chlorocarbonylphenoxy)cyclohexanecarboxylate 
• 1239311-10-4 methyl cis-4-(4-isothiocyanatocarbonylphenoxy)cyclohexane-carboxylate 
• 1239310-90-7 tert-butyl cis-4-(4-methoxycarbonylcyclohexyloxy)benzoate 
• 60344-52-7 4-Benzhydrylidene-cyclohexanol 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 21146-28-1 1-aminocyclohexane-1,4-dicarboxylic acid 

Relevant academic research and scientific papers

Trans-Selective and Switchable Arene Hydrogenation of Phenol Derivatives

A trans-selective arene hydrogenation of abundant phenol derivatives catalyzed by a commercially available heterogeneous palladium catalyst is reported. The described method tolerates a variety of functional groups and provides access to a broad scope of trans-configurated cyclohexanols as potential building blocks for life sciences and beyond in a one-step procedure. The transformation is strategically important because arene hydrogenation preferentially delivers the opposite cis-isomers. The diastereoselectivity of the phenol hydrogenation can be switched to the cis-isomers by employing rhodium-based catalysts. Moreover, a protocol for the chemoselective hydrogenation of phenols to cyclohexanones was developed.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma

Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inhibitors. A versatile synthesis starting from 4-methoxypyridine enabled an efficient exploration of the SAR, giving a lead molecule with potent CETP inhibition in human plasma. The subsequent optimization focused on improvement of pharmacokinetics and mitigation of off-target liabilities, such as CYP inhibition, whose improvement correlated with increased lipophilic efficiency. The effort led to the identification of an achiral, carboxylic acid-bearing compound 16 (TAP311) with excellent pharmacokinetics in rats and robust efficacy in hamsters. Compared to anacetrapib, the compound showed substantially reduced lipophilicity, had only modest distribution into adipose tissue, and retained potency in hypertriglyceridemic plasma in vitro and in vivo. Furthermore, in contrast to torcetrapib, the compound did not increase aldosterone secretion in human adrenocortical carcinoma cells nor in chronically cannulated rats. On the basis of its preclinical efficacy and safety profile, the compound was advanced into clinical trials.

FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

A nitric oxide-dexamethasone and preparation method and use thereof

The invention relates to nitric oxide donor type hexadecadrol as well as a preparation method and application thereof. The nitric oxide donor type hexadecadrol as a compound is obtained by enabling nitrous acid ester to be connected with hexadecadrol through ethyl cyclohexanecarboxylate; the in-vitro antiinflammatory activity of the nitric oxide donor type hexadecadrol is better than that of the hexadecadrol; besides, the nitric oxide donor type hexadecadrol can restrain the growth of methicillin-resistant staphylococcus aureus (MRSA) in vitro, restrain the formation of MRSA biomembrane, and lead to the death of bacteria in the MRSA biomembrane. In addition, the compound can notably increase the survival rate of mice in MRSA sepsis lethal models, reduces the inflammation pathology damage of the mice in sub-sepsis models, decreases the constant value number of bacteria, and has notable advantages in the respect of preventing and treating MRSA sepsis.

SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

NOVEL CARBOXYLIC ACID COMPOUNDS USEFUL FOR INHIBITING MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1

The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salts, thereof, where R, X, A, E, and G are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation.

PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

BICYCLIC HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Bicyclic heteroaryl derivatives of Formula 1, and pharmaceutically acceptable salts, isomers, hydrates and solvates thereof can selectively and effectively inhibit DGAT1, and thus can be useful as medicines for effectively treating dangerous diseases such as obesity, type 2 diabetes, abnormal lipidemia, metabolic syndrome (syndrome X) and the like, which are caused by DGAT1, with no adverse side effects.

THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.